Navigation Links
NIH, Gates Foundation and Colorado State team up to find new approach to a TB vaccine
Date:1/25/2011

WHAT: A team of U.S. and European researchers have found that a new vaccine strategy tested in mice provides stronger, more long-lasting protection from tuberculosis (TB) infection than the vaccine currently used in humans, known as BCG. Their findings were published online on January 23rd in the journal Nature Medicine.

The study was co-funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation. It was coordinated by the NIAID-funded TB Vaccine Testing and Research Materials program at Colorado State University, an initiative to speed the development of new TB vaccines and treatments.

Caused by the bacterium Mycobacterium tuberculosis (Mtb), TB remains one of the major causes of disability and death worldwide, with an estimated 1.7 million deaths in 2009 and increasing rates of drug-resistant disease. The BCG vaccine, the only one approved for human use, provides some protection against initial TB illness but does not prevent latent infection, in which Mtb persists in human cells for years and may later develop into active disease.

In this study, the researchers combined two proteins previously found to improve the BCG vaccine's effectiveness with a new component, a stress response protein that mice produce throughout the TB infection process. This three-component vaccine, known as H56, was administered to uninfected mice before and after BCG vaccination. Six weeks later, the mice were exposed to Mtb. The multistage strategy not only protected against initial illness, but controlled reactivation of latent infection and reduced Mtb levels in the lungs more effectively than BCG alone. Because of the success of this study, the vaccine candidate is now entering clinical development.


'/>"/>

Contact: Nalini Padmanabhan
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1

Related medicine news :

1. Ghrelin mitigates liver fibrosis in animal models; regulates human fibrosis
2. Bill & Melinda Gates, Asian Parliamentary Group, Win 2010 United Nations Population Award
3. Long Island Press Investigates Big Tobacco's Lobby to Kill Indian Cigarette Trade
4. SC Johnson and Bill & Melinda Gates Foundation Unite to Combat Malaria
5. Food Safety Law Firm Investigates Major Outbreak of E. coli Linked To Lettuce
6. Georgia Tech awarded Gates Foundation grant for innovative global health research
7. Drug mitigates toxic effects of radiation in mice
8. AIDS 2010 delegates and speakers unite in support of full funding for the Global Fund, the next milestone in drive for universal access
9. Thesis investigates characteristics of society using sports activities as research tool
10. UI study investigates variability in mens recall of sexual cues
11. BUSM investigates cellular mechanisms leading to immune response in airway epithelium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... who quickly add weight and length may be showing a ... In adults, certain genes have been linked to increased ... gains in fat and lean muscle, the researchers said. ... and taller. By ages 2 and 3, however, these genes ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Disparities in Diabetes Prevention and Management Among Most ... Foundation (Foundation), the philanthropic arm of Merck & ... Alliance to Reduce Disparities in Diabetes (Alliance), a ... those populations most at risk for diabetes -- ...
... Diamonds and Jewels ... Jet Set Getaways ... Exclusive ... to Cure Paralysis BAL HARBOUR, Fla., Feb. 25 ... designers and the highest concentration of world-class jewelers and ... dazzling treasures for Destination Fashion 2009,s silent ...
... Discovery of brain area responsible for link could lead to ... -- The memories and emotions that people associate with ... a part of the brain where the wiring for memories ... study says. , The finding, published Feb. 24 in ...
... Medicine Featured March 7-12 in San Diego ... Interventional Radiology (SIR) will present the latest research ... bone cancer; herniated disks; peripheral arterial disease (PAD) ... its 34th Annual Scientific Meeting, March 7-12 at ...
... 24 states now reporting widespread activity, the nation,s infectious ... to educate their customers on when antibiotics are the ... good. , Several grocery store chains nationwide began offering ... to cold and flu season, despite the fact that ...
... itself Kurt Salmon Associates saysNEW YORK, Feb. 25 ... less on prescription drugs this year versus last ... to Kurt Salmon Associates, recent evaluation of more than ... a continued shift towards lower-cost generic drugs and an ...
Cached Medicine News:Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 2Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 3Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 4Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 5Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 6Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 2Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 3Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 4Health News:Why Music Triggers a Walk Down Memory Lane 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 4Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 5Health News:Health experts urge supermarket pharmacies to 'get smart' about free antibiotics 2Health News:Consumers Spending Less on Prescription Drugs 2
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... Oct. 20, 2014  Indianapolis interventional medical device ... Toronto -based 3D visualization leader Synaptive ... Neurological Surgeons Annual Meeting that they have joined ... surgery. The collaboration is the first of its ... improve patient outcomes. NICO,s BrainPath® interventional access technology ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... , , ... ... Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... ...
... U.S. Cancer Centers Involved , ... , , ... ... HUNTINGTON BEACH, California and AMSTERDAM , ...
Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 2Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 3Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 4Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 5
... ReZoom intraocular lens is a second-generation ... patients with greater independence from glasses than ... provides a range of vision that monfocals ... Optics technology distributes light over five optic ...
... best potential for quality vision with ACRYSOF ... for spherical aberration by addressing the effects ... accomplished without increasing edge thickness. Human ... design that provides improved image quality.,MTF (measured ...
... FRx Defibrillator was designed to be as ... Defibrillator and shares many of its features, ... The Philips HeartStart Home Defibrillator is an ... for home use by untrained users. Although ...
Designed to meet the demanding requirements of scientific and laboratory,applications. Special cabinet incorporates industrial quality with a,heavy duty refrigeration system to maintain your valu...
Medicine Products: